Search Results - "AMIN, Dhara N"

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics by Amin, Dhara N., Campbell, Marcia R., Moasser, Mark M.

“…Many types of human cancer are characterized by deregulation of the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors. In some…”
Get full text

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells by Amin, Dhara N, Sergina, Natalia, Lim, Lionel, Goga, Andrei, Moasser, Mark M

“…HER2 (human epidermal growth factor receptor-2)-amplified tumours are characterized by constitutive signalling via the HER2-HER3 co-receptor complex. Although…”
Get more information

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver by Amin, Dhara N, Sergina, Natalia, Ahuja, Deepika, McMahon, Martin, Blair, Jimmy A, Wang, Donghui, Hann, Byron, Koch, Kevin M, Shokat, Kevan M, Moasser, Mark M

“…About 25% of breast cancers harbor the amplified oncogene human epidermal growth factor receptor 2 (HER2) and are dependent on HER2 kinase function,…”
Get more information

Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F by COMA, Silvia, AMIN, Dhara N, SHIMIZU, Akio, LASORELLA, Anna, IAVARONE, Antonio, KLAGSBRUN, Michael

“…Id proteins (Id1 to Id4) are helix-loop-helix transcription factors that promote metastasis. It was found that Semaphorin 3F (SEMA3F), a potent inhibitor of…”
Get full text

Disentangling multidimensional spatio-temporal data into their common and aberrant responses by Chang, Young Hwan, Korkola, James, Amin, Dhara N, Moasser, Mark M, Carmena, Jose M, Gray, Joe W, Tomlin, Claire J

“…With the advent of high-throughput measurement techniques, scientists and engineers are starting to grapple with massive data sets and encountering challenges…”
Get full text

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors by AMIN, Dhara N, HIDA, Kyoko, BIELENBERG, Diane R, KLAGSBRUN, Michael

“…Epidermal growth factor (EGF) receptor family members are expressed by tumor cells and contribute to tumor progression. The expression and activity of EGF…”
Get full text

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers by Amin, Dhara N, Ahuja, Deepika, Yaswen, Paul, Moasser, Mark M

“…The requisite role of HER3 in HER2-amplified cancers is beyond what would be expected as a dimerization partner or effector substrate and it exhibits a…”
Get full text

Tumor-associated endothelial cells with cytogenetic abnormalities by HIDA, Kyoko, HIDA, Yasuhiro, AMIN, Dhara N, FLINT, Alan F, PANIGRAHY, Dipak, MORTON, Cynthia C, KLAGSBRUN, Michael

“…Tumor angiogenesis is necessary for solid tumor progression and metastasis. Tumor blood vessels have been shown to differ from normal counterparts, for…”
Get full text

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study by Lasater, Elisabeth A., Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Barrett, Kathy, Rys, Ryan N., Oeh, Jason, Lin, Eva, Sterne‐Weiler, Tim, Ingalla, Ellen Rei, Go, MaryAnn, Yu, Shang‐Fan, Krem, Maxwell M., Arthur, Chris, Hahn, Uwe, Johnston, Anna, Karur, Vinit, Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Polson, Andrew G., Chang, YiMeng, Wever, Claudia, Johnson, Nathalie A., Jiang, Yanwen, Hirata, Jamie, Sampath, Deepak, Musick, Lisa, Flowers, Christopher R., Wertz, Ingrid E.

“…The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro‐survival BCL‐2…”
Get full text

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin by Campbell, Marcia R., Zhang, Hui, Ziaee, Shabnam, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Oeffinger, Julie, Amin, Dhara N., Ahuja, Deepika, Moasser, Mark M., Park, Catherine C.

“…The central role of HER2 as the disease driver and HER3 as its essential partner has made them rational targets for the treatment of HER2-amplifed breast…”
Get full text

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib by Amin, Dhara N, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Moasser, Mark M

“…The clinical impact of HER2 inhibitors in the treatment of HER2-amplified breast cancers has been largely confined to chemotherapy combination regimens, since…”
Get full text

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells by Amin, Dhara N., Bielenberg, Diane R., Lifshits, Eugene, Heymach, John V., Klagsbrun, Michael

“…Epidermal growth factor receptor (EGFR) targeting agents such as kinase inhibitors reduce tumor growth and progression. We have previously reported that EGFR…”
Get full text

Neuregulin-regulated gene expression in mammary carcinoma cells by Amin, Dhara N., Tuck, David, Stern, David F.

“…Recent studies have suggested that autocrine production of Neuregulin (NRG), a growth factor that activates members of the Epidermal Growth Factor…”
Get full text

Gene expression profiling of ErbB receptor and ligand-dependent transcription by AMIN, Dhara N, PERKINS, Archibald S, STERN, David F

“…Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms…”
Get full text

A TORC2-Akt feedforward topology underlies HER3 resiliency in HER2-amplified cancers by Amin, Dhara N., Ahuja, Deepika, Yaswen, Paul, Moasser, Mark M.

“…The requisite role of HER3 in HER2-amplified cancers is beyond what would be expected as a dimerization partner or effector substrate and it exhibits a…”
Get full text

Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1 by Amin, Dhara N., Oeh, Jason, Zindal, Anuradha, Musick, Lisa, Hirata, Jamie, Mobasher, Mehrdad, Polson, Andy, Sampath, Deepak, Wertz, Ingrid E.

“…Venetoclax, a potent, orally bioavailable inhibitor that selectively targets BCL-2 and induces intrinsic apoptosis, is currently approved for the treatment of…”
Get full text

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study by Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Oeh, Jason, Lin, Eva, Zindal, Anuradha, Go, MaryAnn, Yu, Shang-Fan, Krem, Maxwell, Arthur, Chris, Hahn, Uwe, Johnston, Anna M., Karur, Vinit G., Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam Yuen, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Lasater, Elizabeth A., Polson, Andrew G., Chang, YiMeng, Hirata, Jamie, Musick, Lisa, Sampath, Deepak, Flowers, Christopher R., Wertz, Ingrid E.

“…Purpose: Treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge, largely due to the genetic…”
Get full text

Effective treatment of HER2-amplified breast cancer by targeting HER3 and [beta]1 integrin by Campbell, Marcia R, Zhang, Hui, Ziaee, Shabnam, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Oeffinger, Julie, Amin, Dhara N, Ahuja, Deepika, Moasser, Mark M, Park, Catherine C

“…The central role of HER2 as the disease driver and HER3 as its essential partner has made them rational targets for the treatment of HER2-amplifed breast…”
Get full text

Abstract 3043: Akt-mTorc2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers by Amin, Dhara N., Ahuja, Deepika, Ducker, Gregory S., Yaswen, Paul, Shokat, Kevan, Moasser, Mark

“…HER2 amplified breast cancers are characterized by constitutive HER3 phosphorylation. Efforts to target the functionally relevant HER2-HER3 signaling complex…”
Get full text

Abstract 1653: Highly effective treatment of HER2-amplified breast cancers through the complete inactivation of the HER2-HER3 tumorigenic driver by Amin, Dhara N., Sergina, Natalia, Ahuja, Deepika, McMahon, Martin, Wang, Donghui, Hann, Byron, Shokat, Kevan, Moasser, Mark M.

“…Approximately 25% of breast cancers are driven by amplification of the HER2 oncogene and over-activity of the HER2-HER3 signaling complex. It is a promising…”
Get full text